Chromosome 21 rearrangement in acute biphenotypic leukemia.
A patient with myelodysplastic syndrome (MDS) and a 47,XY,+21 karyotype at diagnosis, was documented to have a clonal chromosome 21 rearrangement, i(21q), four months before transformation to acute biphenotypic leukemia. For 4 months after transformation, isochromosome 21 persisted while the patient was receiving treatment with zidovudine. Vitamin D3 was added to zidovudine for an additional month, during which time the trisomy 21 clone reappeared as the predominant cell population. The unique aspects of this patient are the atypical evolution of chromosome 21, the transformation to biphenotypic leukemia, and the occurrence of i(21q) associated with biphenotypic leukemia evolving from an MDS.
Theodossiou
C
C
Tumor Cytogenetics Laboratory, Poly Annenberg Levy Hematology Center, Mount Sinai School of Medicine, New York.
Scalise
A
A
Silverman
L
L
Najfeld
V
V
D000754:Anemia, Refractory, with Excess of Blasts / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D018826:CD13 Antigens; D002471:Cell Transformation, Neoplastic; D002762:Cholecalciferol / Q000627:therapeutic use; D002891:Chromosomes, Human, Pair 21; D015973:Gene Expression Regulation, Leukemic; D015321:Gene Rearrangement; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D014314:Trisomy; D015215:Zidovudine / Q000627:therapeutic use
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015375:Receptors, Interleukin-2; D002762:Cholecalciferol; D015215:Zidovudine; D018826:CD13 Antigens